Investment

Investment Opportunity  •  Next Steps

Investment Summary

Magellan Stem Cells aims to be the world first and leading supplier of off-the-shelf allogeneic stem cell therapy in the treatment of Osteoarthritis

Magellan Stem Cells product MAG200 is an exciting investment opportunity for strategic investors, addressing a global and currently unmet medical need. Our 13 years of intensive research which includes pre-clinical research and Phase 1-2 trials for clinical safety and efficacy, our product MAG200 has been developed as an off-the-shelf allogeneic stem cell treatment for osteoarthritis.

In the first quarter of 2025, Magellan Stem Cells product MAG200 will enter a pivotal phase three clinical trial.  Our trial synopsis has been reviewed, adjusted and accepted by the TGA and other international regulatory bodies (EMA, MHRA, FDA). The commencement of this world first phase three trial with a proven allogeneic stem cell line presents a prime opportunity for investors who value emerging technologies in biomedical research.

With unique proprietary information and intellectual property, supported by strong patent portfolio protection, Magellan Stem Cells product MAG200 is a scalable global treatment with the potential for significant market penetration. 

Investment Opportunity

Magellan Stem Cells is looking for like-minded investment partners

We are in strategic discussions with interested investors and offering a minority interest in Magellan Stem Cells. We are looking for significant investment to help support the P3 clinical trial.

  • There is a very large potential international market for an efficacious treatment of osteoarthritis 
  • More than 100 million people have in Europe, UK, USA, Canada, Japan and Australia are suffering from osteoarthritis 
  • The estimated cost of an approved product MAG200 treatment is less than 20% of the cost of joint replacement
  • Magellan Stem Cells is expecting to generate substantial and increasing revenues from 2028 onwards and is projecting a positive EBITDA in the first year of commercial sales.

Magellan Stem Cells is expecting to generate substantial and increasing revenues from 2028 onwards and is projecting a positive EBITDA in the first year of commercial sales.

Investment Enquiry

Board of Directors

Lou Panaccio
Non-Executive Chairman

Mr Panaccio is a Chartered Accountant with a wealth of executive management experience in business and healthcare services. Mr Panaccio has been the Chief Executive Officer of Monash IVF and Executive Director of Melbourne Pathology. He was also a Non-executive Director of ASX-listed Genera Biosystems Limited.

Mr Panaccio currently holds positions on the boards of ASX and NASDAQ listed Avita Therapeutics Inc. ASX50 company Sonic Healthcare Limited, ASX-listed Rhythm Non-executive Director.

peter-hansen

Peter Hansen

Executive Director
Peter has more than thirty years of experience in founding and leading four biotechnology and medical related companies (Australia, USA and Asia). He has chaired four public companies (Australia and UK) and three IPO’s. His focus on marketing, manufacturing technologies/costs (Australia, Singapore, Malaysia), research collaborations and international licensing.

Ross Williams

Executive Director
Ross is a Chartered Accountant, MBA with over thirty years Finance and Accounting experience in Multinational Public and Private Companies, including then years as GM of a leading Allied Health company. He is a director of Melbourne Stem Cell Centre Research and Australian Osteoarthritis Clinic.
magellan-michael

Michael Kenihan

Executive Director
Michael is past president and CEO of Sports Medicine Australia and a qualified Sports Physiotherapist. Previously GM of Lifecare, a leading Allied Health Company, he is now Director of Melbourne Stem Cell Centre Research and Australian Osteoarthritis Clinic.
magellan-julien

Julien Freitag

Executive Director
Associate Professor Julien Freitag, MBBS, BMedSci is a leading musculoskeletal specialist and sport and exercise physician. He has published numerous internationally regarded journal articles in the area of regenerative medicine. He is the head of Magellan’s Clinical and Scientific Advisory Board.

Management Team

Kiran Shah

Head Scientific Officer
Kiran has significant clinical research experience in biomedical sciences having completed her post-doctoral work at global bio-tech conglomerate CSL within the area of embryonic stem cells and cell culturing. Dr Shah heads Magellan’s R&D and has established their certified Cleanroom Laboratory in Melbourne.
magellan-julien

Julien Freitag

Chief Medical Officer
Associate Professor Julien Freitag, MBBS, BMedSci is a leading musculoskeletal specialist and sport and exercise physician. He has published numerous internationally regarded journal articles in the area of regenerative medicine. He is the head of Magellan’s Clinical and Scientific Advisory Board.
richard-price

Richard Price

Corporate Advisory Board
Richard has had a significant career in the banking sector, including twenty-five with Macquarie Group as an Executive Director providing strategic and financial advice to leading Australian and International companies. He sits as a council member on the National Library of Australia
Renee-Headshot

Renee Castelluccio

Executive Assistant
Renee has background as a practice nurse and experienced clinical and office manager performs the role of coordinating activities of the Board and other senior Management team members. This role extends to coordinating clinical P 1 to P3 trial activities.

Next Steps

We welcome your interest and enquiries in investing in Magellan Stem Cells and its product MAG200 in preparation for P3 trial. Following is an outline of the steps involved to secure your investment.

  1. Complete Non-Disclosure Agreement

  2. Supply and review of Magellan’s investment information

  3. Confirm Expression of Interest and Key Terms

  4. Invitation to Magellan Data room

  5. Detailed Q&A including medical and scientific matters

  6. Review Legal Documentation

  7. Complete Negotiations and Finalise Agreements

  8. Execute Capital Transaction

© All Rights Reserved 2024  |  Privacy policy  |  Terms of use

Investment Enquiry

Magellan are pleased to announce the results of our Phase 1/2 allogenic trial. The research findings are published in Osteoarthritis and Cartilage Open the open-access journal of Osteoarthritis Research Society International (OARSI), which publishes the evidence-based, international consensus guidelines on osteoarthritis management.  

Australian Health Minister announced a $7 million grant to Magellan Stem Cells – read more here

Should you want further information regarding our results or media release please email info@magellanstemcells.com.au or call 03 9270 8080.

Download the full Investor Presentation